Circulating tumour DNA as a decision-making tool: tumour-informed versus tissue-free assays, minimal residual disease after surgery, and whether a molecular relapse signal should change what treatment a patient receives.
uRARE-seq is a tumor-naive urine cell-free RNA (cfRNA) sequencing approach, applied to 683 urine samples from patients with cancer and controls. In the training cohort (100 controls, 151 bladder cancer samples), the detection model reached an AUC of 0.97, with a sensitivity of 95% at 90% specificity.
In a prognostic analysis nested within the phase 2 c-TRAK TN trial, a tissue-free ctDNA assay detected molecular residual disease in 54 of 159 patients (34.0%) with early triple negative breast cancer, and detection was strongly associated with recurrence risk (HR, 27.2).
Retrospective subset analysis of the CIRCULATE-Japan GALAXY registry (298 patients with resected colorectal liver metastases) testing whether ctDNA-defined molecular residual disease (MRD) status can identify who actually benefits from adjuvant chemotherapy (ACT) after liver resection